Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo controlled study assessing the efficacy and safety of vilazodone and discovering genetic markers associated with response in patients with major depressive disorder

Trial Profile

A randomized, double-blind, placebo controlled study assessing the efficacy and safety of vilazodone and discovering genetic markers associated with response in patients with major depressive disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2018

At a glance

  • Drugs Vilazodone (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Genaissance Pharmaceuticals
  • Most Recent Events

    • 30 Mar 2018 Results (n=2218) of post-hoc analysis of four randomized trials assessing efficacy in subgroups of patients with major depressive disorder, were published in the International Clinical Psychopharmacology.
    • 09 Oct 2013 Pooled post-hoc analysis assessing sustained response presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
    • 09 Oct 2013 Pooled post-hoc analysis assessing the effects of vilazodone on anxiety presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top